肿瘤药学2018，Vol.8Issue(1)：108-111,116,5.DOI:10.3969/j.issn.2095-1264.2018.01.25
肿瘤患者应用重组人粒细胞集落刺激因子致严重不良反应13例临床分析
Cases Analysis of Serious Adverse Effects Caused by rhG-CSF on 13 Cancer Patients
符一岚 1曹丽芝 1龚倩 1谌赟 1付滢舟 1黄平1
作者信息
- 1. 湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院 药学部临床药学室,湖南 长沙,410013
- 折叠
摘要
Abstract
Objective To learn the causes and characteristics of adverse reactions induced by recombinant human granulocyte colony stimulating factor (rhG-CSF) and to provide references for safe use in clinical practice. Methods In order to extract effective cases for this study, the author has censused and analyzed the rhG-CSF adverse effect cases reported in National Adverse Drug Effect Monitoring System from 1st January 2014 to 1st May 2017. Results There were 13 patients who met the inclusion criteria, including 2 males and 11 females. Among them, 12 patients were under treatment by hypodermic injection, 1 patient were under intravenous injection. In these cases, 76.92% of them were breast cancer patient under chemotherapy with serve myelosuppression. The medicine causing serve adverse effect were made domestically and ferment by colibacillus, which mainly brings side effect to the respiratory system, parasympathetic division, gastrointestinal system, musculoskeletal system and ect. The adverse effect mainly presented as chest suppression, dyspnea, hidrosis, abdomen pain ect. In this study, there were 2 patients who were allergic to filgrastim. After using lenograstim, no allergic effect presented. Conclusion As a biological agent which brings adverse effect, the rhG-CSF should be under serve monitoring during clinic practice. Glycosylated rhG-CSF (lenograstim) can be a replacement for patients who are allergic to rhG-CSF (filgrastim) ferment by colibacillus.关键词
重组人粒细胞集落刺激因子/不良反应/分析/化疗Key words
Recombinant human granulocyte colony stimulating factor/Adverse reaction/Analysis/Chemotherapy分类
医药卫生引用本文复制引用
符一岚,曹丽芝,龚倩,谌赟,付滢舟,黄平..肿瘤患者应用重组人粒细胞集落刺激因子致严重不良反应13例临床分析[J].肿瘤药学,2018,8(1):108-111,116,5.
